Payment overview · 2025
General Payments
$2,784.08
112 reported records · 25 companies
Healthcare provider profile · identity verified
Jeffrey Scott Holmes, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HURRICANE, WV · NPI 1982665329
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Scott Holmes, MD received $2,784.08 in general payments during 2025 across 112 reported records.
Smith+Nephew, Inc. accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $930.98 | 33.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $418.79 | 15.0% | 21 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $187.98 | 6.8% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $162.93 | 5.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $139.51 | 5.0% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $137.72 | 5.0% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $126.89 | 4.6% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $110.93 | 4.0% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $83.39 | 3.0% | 5 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $60.39 | 2.2% | 2 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $53.08 | 1.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.86 | 1.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.13 | 1.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.42 | 1.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.84 | 1.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.24 | 1.0% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $24.16 | 0.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.30 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.40 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.54 | 0.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.43 | 0.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.72 | 0.6% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $16.37 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.09 | 0.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $15.99 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,997.42 | 110 |
| Travel and Lodging | $786.66 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JOURNEY II Normalized: journey ii |
Device | Smith+Nephew, Inc. | $842.30 | 3 | 2025 |
Source payment records
|
|||||
| REAL INTELLIGENCE Normalized: real intelligence |
Device | Smith+Nephew, Inc. | $792.13 | 3 | 2025 |
Source payment records
|
|||||
| TANDEM Normalized: tandem |
Device | Smith+Nephew, Inc. | $792.13 | 3 | 2025 |
Source payment records
|
|||||
| K-15 PORK Normalized: k 15 pork |
Device | Smith+Nephew, Inc. | $559.35 | 3 | 2025 |
Source payment records
|
|||||
| Legion Revision Normalized: legion revision |
Device | Smith+Nephew, Inc. | $553.88 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $363.75 | 18 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $187.98 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $147.21 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $141.98 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $139.51 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.43 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.71 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $97.19 | 12 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $83.39 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.10 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.94 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $64.03 | 4 | 2025 |
Source payment records
|
|||||
| OR3O Dual Mobility Normalized: or3o dual mobility |
Device | Smith+Nephew, Inc. | $62.44 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $59.85 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $58.26 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $55.04 | 3 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $53.08 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $42.38 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.42 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.84 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 206 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
206 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
206 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
360 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 787 | 199 |
| Levothyroxine Sodium | Levothyroxine Sodium | 711 | 151 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 656 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 571 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 547 | 143 |
| Furosemide | Furosemide | 531 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 454 | 120 |
| Lisinopril | Lisinopril | 419 | 116 |
| Eliquis | Apixaban | 360 | 56 |
| Sertraline Hcl | Sertraline Hcl | 342 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 285 | 82 |
| Simvastatin | Simvastatin | 278 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 265 | 61 |
| Gabapentin | Gabapentin | 263 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 253 | 70 |
| Alprazolam | Alprazolam | 251 | 53 |
| Omeprazole | Omeprazole | 247 | 79 |
| Oxycodone Hcl | Oxycodone Hcl | 246 | 21 |
| Trazodone Hcl | Trazodone Hcl | 238 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 235 | 57 |
| Metformin Hcl | Metformin Hcl | 234 | 73 |
| Losartan Potassium | Losartan Potassium | 222 | 63 |
| Montelukast Sodium | Montelukast Sodium | 221 | 63 |
| Jardiance | Empagliflozin | 206 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 201 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 197 | 50 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 197 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 50 |
| Potassium Chloride | Potassium Chloride | 196 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 180 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 178 | 29 |
| Tramadol Hcl | Tramadol Hcl | 177 | 41 |
| Buspirone Hcl | Buspirone Hcl | 158 | 32 |
| Glimepiride | Glimepiride | 150 | 40 |
| Carvedilol | Carvedilol | 149 | 37 |
| Famotidine | Famotidine | 144 | 39 |
| Entresto | Sacubitril/Valsartan | 139 | 11 |
| Donepezil Hcl | Donepezil Hcl | 138 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 47 |
| Ozempic | Semaglutide | 131 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 31 |
| Allopurinol | Allopurinol | 126 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 126 | 30 |
| Methylprednisolone | Methylprednisolone | 126 | 101 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 36 |
| Mirtazapine | Mirtazapine | 121 | 28 |
| Myrbetriq | Mirabegron | 116 | 14 |
| Clonazepam | Clonazepam | 112 | 24 |
| Ezetimibe | Ezetimibe | 109 | 33 |
| Lorazepam | Lorazepam | 108 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 28 |
| Prednisone | Prednisone | 106 | 69 |
| Baclofen | Baclofen | 104 | 15 |
| Valsartan | Valsartan | 104 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 49 |
| Levetiracetam | Levetiracetam | 91 | 14 |
| Alendronate Sodium | Alendronate Sodium | 90 | 22 |
| Trulicity | Dulaglutide | 88 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 31 |
| Methocarbamol | Methocarbamol | 84 | 27 |
| Clonidine Hcl | Clonidine Hcl | 83 | 25 |
| Meloxicam | Meloxicam | 82 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 19 |
| Bupropion Xl | Bupropion Hcl | 81 | 22 |
| Memantine Hcl | Memantine Hcl | 81 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 80 | suppressed |
| Januvia | Sitagliptin Phosphate | 79 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 23 |
| Atenolol | Atenolol | 72 | 21 |
| Xarelto | Rivaroxaban | 71 | 13 |
| Pregabalin | Pregabalin | 70 | 18 |
| Finasteride | Finasteride | 69 | 17 |
| Sucralfate | Sucralfate | 69 | 19 |
| Spironolactone | Spironolactone | 68 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 67 | suppressed |
| Celecoxib | Celecoxib | 67 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 33 |
| Temazepam | Temazepam | 66 | suppressed |
| Amoxicillin | Amoxicillin | 65 | 56 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 61 | suppressed |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Lactulose | Lactulose | 59 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 19 |
| Torsemide | Torsemide | 58 | 16 |
| Novolog Flexpen | Insulin Aspart | 57 | 14 |
| Synthroid | Levothyroxine Sodium | 56 | 17 |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 16 |
| Divalproex Sodium | Divalproex Sodium | 53 | suppressed |
| Linzess | Linaclotide | 53 | 13 |
| Ibuprofen | Ibuprofen | 52 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 14 |
| Diazepam | Diazepam | 51 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 50 | 13 |
| Fenofibrate | Fenofibrate | 48 | 17 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 48 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 13 |
| Carisoprodol | Carisoprodol | 47 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 39 |
| Farxiga | Dapagliflozin Propanediol | 45 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 39 |
| Lansoprazole | Lansoprazole | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Ramelteon | Ramelteon | 43 | 19 |
| Meclizine Hcl | Meclizine Hcl | 42 | 25 |
| Risperidone | Risperidone | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Phenobarbital | Phenobarbital | 37 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Enbrel Sureclick | Etanercept | 36 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Cefdinir | Cefdinir | 34 | 30 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 14 |
| Primidone | Primidone | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 31 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 12 |
| Metronidazole | Metronidazole | 31 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | 11 |
| Nabumetone | Nabumetone | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | 11 |
| Valacyclovir | Valacyclovir Hcl | 27 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 21 |
| Methimazole | Methimazole | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Felodipine Er | Felodipine | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | 12 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Actos | Pioglitazone Hcl | 11 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,784.08 · 112 records | Smith+Nephew, Inc. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COLLAGENASE SANTYL, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GIMOTI, JARDIANCE, JOURNAVX, JOURNEY II, K-15 PORK, Kerendia, Legion Revision, MOUNJARO, NURTEC ODT, OR3O Dual Mobility, OTEZLA, Ozempic, PROLIA, Paradise Ultrasound Renal Denervation System, QULIPTA, REAL INTELLIGENCE, REPATHA, REXULTI, Rybelsus, TANDEM, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, VYNDAMAX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error